New three-year data for Roche ’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)
91% of infants treated withEvrysdi in the FIREFISH study were still alive at three yearsInfants treated withEvrysdi maintained or continued to improve in measures of motor function, including their ability to sit without support for 5 and 30 secondsEvrysdi has proven efficacy in infants and adults, with over 5,000 patients treated to dateBasel, 29 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new three-year data from the FIREFISH study, including one-year data from the open label extension, reinforcing the long-term efficacy and safety of Evrysdi ® (risdiplam) in infants with symptomatic Type 1 spinal mu...
Source: Roche Media News - April 29, 2022 Category: Pharmaceuticals Source Type: news
New three-year data for Roche ’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)
91% of infants treated withEvrysdi in the FIREFISH study were still alive at three yearsInfants treated withEvrysdi maintained or continued to improve in measures of motor function, including their ability to sit without support for 5 and 30 secondsEvrysdi has proven efficacy in infants and adults, with over 5,000 patients treated to dateBasel, 29 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new three-year data from the FIREFISH study, including one-year data from the open label extension, reinforcing the long-term efficacy and safety of Evrysdi ® (risdiplam) in infants with symptomatic Type 1 spinal mu...
Source: Roche Investor Update - April 29, 2022 Category: Pharmaceuticals Source Type: news
Trial May Set Standard for Steroid Therapy in Duchenne Muscular Dystrophy
(MedPage Today) -- SEATTLE -- Prednisone or deflazacort given every day were superior to prednisone on a 1o-days-on, 10-days-off schedule for boys with Duchenne muscular dystrophy (DMD), a researcher reported.
In the international randomized... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - April 27, 2022 Category: Endocrinology Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Basel, 25 April 2022Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early...
Source: Roche Media News - April 25, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early-stage non-small cel...
Source: Roche Investor Update - April 25, 2022 Category: Pharmaceuticals Source Type: news
Optimal Treatment Regimen for Muscular Dystrophy Identified? Optimal Treatment Regimen for Muscular Dystrophy Identified?
Children treated with either daily prednisone or daily deflazacort (Emflaza) have better motor function than those receiving a standard prednisone regimen.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 6, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
New data for Roche ’s OCREVUS (ocrelizumab) show benefit in disability progression and cognitive decline in both secondary progressive and primary progressive multiple sclerosis
75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression (NEP) in a one-year interim analysis of CONSONANCE study70% of patients with SPMS and PPMS demonstrated stable or improved cognition after one year of OCREVUS treatment in CONSONANCESeparate analysis on treatment disparities showed fewer Black and Hispanic patients with MS initiate high-efficacy treatments within two years of diagnosisData at AAN support the body of evidence for OCREVUS more than 450,000 patient years and more than 225,000 patients treated globallyBasel, 04 April 2022 -...
Source: Roche Media News - April 4, 2022 Category: Pharmaceuticals Source Type: news
Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of Duchenne Muscular Dystrophy
Pratteln, Switzerland, March 29, 2022– Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc (US: private) announce the initiation of a rolling new drug application (NDA) submission to the U.S. Food and Drug Administration (FDA)... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 29, 2022 Category: Drugs & Pharmacology Source Type: news
Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting
First data showing OCREVUS treatment effect on disability progression in non-active secondary progressive multiple sclerosis and further data in primary progressive MS will be presentedEvrysdi data continue to demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophyLonger-term efficacy and safety forEnspryng inneuromyelitisoptica spectrum disorder reinforce previously seen resultsAdditional data across neurological disorders, including Alzheimer ’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatmentBasel, 25 March...
Source: Roche Investor Update - March 25, 2022 Category: Pharmaceuticals Source Type: news
Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting
First data showing OCREVUS treatment effect on disability progression in non-active secondary progressive multiple sclerosis and further data in primary progressive MS will be presentedEvrysdi data continue to demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophyLonger-term efficacy and safety forEnspryng inneuromyelitisoptica spectrum disorder reinforce previously seen resultsAdditional data across neurological disorders, including Alzheimer ’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatmentBasel, 25 March...
Source: Roche Media News - March 25, 2022 Category: Pharmaceuticals Source Type: news
New data for Roche ’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA)
Long-term efficacy data from the pivotal SUNFISH study confirm increases in motor function are sustained at three years while adverse events decreased over the same periodPart 2 of SUNFISH showedEvrysdi demonstrated a marked improvement in, orstabilisation of, motor function after two years compared to an untreated external control groupLatest interim results from the RAINBOWFISH study demonstrate that the majority of babies treated withEvrysdi for at least 12 months were able to stand and walk within timeframes typical of healthy babiesMore than 5,000 patients have been treated withEvrysdi to date, from newborns to people...
Source: Roche Investor Update - March 16, 2022 Category: Pharmaceuticals Source Type: news
New data for Roche ’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA)
Long-term efficacy data from the pivotal SUNFISH study confirm increases in motor function are sustained at three years while adverse events decreased over the same periodPart 2 of SUNFISH showedEvrysdi demonstrated a marked improvement in, orstabilisation of, motor function after two years compared to an untreated external control groupLatest interim results from the RAINBOWFISH study demonstrate that the majority of babies treated withEvrysdi for at least 12 months were able to stand and walk within timeframes typical of healthy babiesMore than 5,000 patients have been treated withEvrysdi to date, from newborns to people...
Source: Roche Media News - March 16, 2022 Category: Pharmaceuticals Source Type: news
A Useful Severity Predictor in Muscular Dystrophy? A Useful Severity Predictor in Muscular Dystrophy?
A retrospective study evaluated the relationship between peripheral eosinophil count and muscle strength in pediatric patients with Duchenne muscular dystrophy.First Look (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 9, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Reminder: Invitation to Roche ’s virtual event on key neuromuscular data presented at the 2022 Muscular Dystrophy Association (MDA) scientific and clinical conference
We are pleased to invite investors and analysts to participate in our virtual event onWednesday, 16 March 2022, highlighting Roche data presented during the 2022 Muscular Dystrophy Association - MDA -Virtual Clinical and Scientific Conference, from 13th to 16th March.16:30 – 17:30 CET / 15:30 - 16:30 GMT11:30 – 12:30 am EDT / 8:30 – 9:30 am PDT The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available fordownload at15:30 CET on the day of the event.>click here AgendaWelcomeBruno Eschli, Head of Investor Relations Neuromuscular franchi...
Source: Roche Investor Update - March 9, 2022 Category: Pharmaceuticals Source Type: news
Roche to present new Evrysdi data at MDA 2022 and highlight expanding neuromuscular disease portfolio
Evrysdi ® (risdiplam) data further confirm long-term efficacy and safety data in a broad range of people with spinal muscular atrophy (SMA)Latest interim results from the RAINBOWFISH study demonstrate that the majority of babies treated with Evrysdi for at least 12 months were able to sit, stand and walk within timeframes typical of healthy babiesNew gene therapy data in boys living with Duchenne muscular dystrophy (DMD) reports encouraging results from early stage study supporting its progress into global pivotal Phase III EMBARK studyBasel, 08 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data...
Source: Roche Media News - March 8, 2022 Category: Pharmaceuticals Source Type: news
